We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AcelRx Pharmaceuticals announced a definitive merger agreement to acquire Tetraphase Pharmaceuticals in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx ...